Carlos L. Arteaga, MD, professor of medicine and cancer biology, Vanderbilt-Ingram Cancer Center, discusses the CALGB 40603 trial that examined the neoadjuvant treatment of triple-negative breast cancer (TNBC).

In the study, patients with TNBC were randomized to receive the neoadjuvant standard of care with or without carboplatin, a DNA damaging chemotherapy. By adding carboplatin to the standard of care, the rate of pathologic complete response (pCR) was improved, Arteaga says. Additionally, the rate of pCR in this study could translate into a long-term improvement in outcomes.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

San Antonio Breast Cancer Symposium

Carlos L. Arteaga, MD,discusses the CALGB 40603 trial, a neoadjuvant triple-negative breast cancer trial.

Dr. Arteaga Discusses the CALGB 40603 Trial